1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Centerspace reported third-quarter 2025 net income of $3.19 per diluted share, compared with a loss of $0.40 a year earlier, helped by a $79.5 million gain on real estate sales. Core FFO was $1.19 per diluted share, up from $1.18, but the company lowered its 2025 net income per share outlook to $1.97 to $2.19 from $2.50 to $2.76.
Q3 2025 net income of $3.19 per diluted share, versus a $0.40 loss in Q3 2024; results include a $79.5 million gain on sale of real estate.
Q3 2025 Core FFO of $1.19 per diluted share, up 0.8% from $1.18 a year earlier.
2025 net income per diluted share outlook cut to $1.97 to $2.19 from $2.50 to $2.76; Core FFO outlook narrowed to $4.88 to $4.96 from $4.88 to $5.00.
Same-store NOI rose 4.5% in Q3 2025 year over year; total liquidity was $200.4 million at September 30, 2025.
Ensign Group reported third-quarter 2025 GAAP diluted earnings per share of $1.42, up 6.0% from the prior year, and total revenue of $1.30 billion, up 19.8%. The company raised its full-year 2025 diluted EPS and revenue guidance, which signals higher expected earnings and sales for shareholders.
Q3 GAAP diluted EPS was $1.42 versus $1.34 a year earlier; adjusted diluted EPS was $1.64, up 18.0%
Q3 total revenue was $1.30 billion, up 19.8%; GAAP net income was $83.8 million
2025 diluted EPS guidance raised to $6.48 to $6.54 from $6.34 to $6.46; revenue guidance raised to $5.05 billion to $5.07 billion from $4.99 billion to $5.02 billion
Cash on hand was $443.7 million at September 30, 2025; quarterly dividend of $0.0625 per share was paid
Apple Hospitality REIT reported third-quarter 2025 net income of $50.9 million, down 9.6% from a year earlier, and EPS of $0.21 versus $0.23. The company lowered its full-year 2025 net income guidance by $5.5 million at the midpoint and cut its RevPAR change outlook by 100 basis points, citing year-to-date performance and the potential effect of economic uncertainty and the government shutdown. Shareholders face lower reported earnings and a weaker hotel revenue outlook, though Adjusted EBITDAre guidance was raised slightly.
Q3 2025 net income was $50.9 million versus $56.3 million in Q3 2024; EPS was $0.21 versus $0.23.
Q3 2025 Adjusted EBITDAre was $122.1 million, down 5.3%; Comparable Hotels RevPAR was $124.01, down 1.8%.
2025 net income guidance is $162 million to $175 million, decreased by $5.5 million at the midpoint; Comparable Hotels RevPAR change guidance is (2.00%) to (1.00%), down 100 bps at the midpoint.
2025 Adjusted EBITDAre guidance is $435 million to $444 million, increased by $0.3 million at the midpoint.
Simon Property Group reported third-quarter 2025 results on November 3, 2025, with net income attributable to common stockholders of $606.2 million, or $1.86 per diluted share, up from $1.46 a year earlier. Real Estate FFO rose 5.6% to $3.22 per diluted share, and the company raised its full-year 2025 Real Estate FFO per share outlook to $12.60 to $12.70. The company also raised its quarterly dividend 4.8% to $2.20 per share and closed its acquisition of the remaining 12% interest in The Taubman Realty Group on October 31, 2025.
Q3 2025 net income attributable to common stockholders was $606.2 million, or $1.86 per diluted share, versus $475.2 million, or $1.46, in Q3 2024.
Q3 2025 Real Estate FFO was $1.215 billion, or $3.22 per diluted share, up 5.6% from $3.05 a year earlier.
2025 Real Estate FFO guidance was increased to $12.60 to $12.70 per diluted share.
Quarterly common dividend raised 4.8% to $2.20 per share, payable December 31, 2025 to holders of record on December 10, 2025.
Adeia reported third-quarter 2025 revenue of $87.3 million, up from $86.1 million a year earlier, and GAAP net income of $8.8 million, down from $19.3 million. The company lowered its full-year 2025 revenue outlook to $360 million-$380 million from $390 million-$430 million, mainly because a license agreement with AMD is now unlikely to close in the fourth quarter, and it filed patent infringement litigation against AMD.
Q3 2025 revenue was $87.3 million versus $86.1 million in Q3 2024; GAAP diluted EPS was $0.08 versus $0.17, and non-GAAP diluted EPS was $0.28 versus $0.27.
Full-year 2025 revenue guidance was cut to $360 million-$380 million from $390 million-$430 million; non-GAAP adjusted EBITDA guidance was cut to $202.3 million-$218.3 million from $232.1 million-$266.1 million.
Adeia filed patent infringement litigation against AMD on November 3, 2025.
The board declared a quarterly dividend of $0.05 per share, payable December 15, 2025, to holders of record on November 24, 2025.
TG Therapeutics reported third quarter 2025 total revenue of $161.7 million, up from $83.9 million a year earlier, and net income of $390.9 million, which includes a non-recurring income tax benefit of approximately $365.0 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to approximately $585 million and its global revenue target to approximately $600 million, and authorized a new $100 million share repurchase program.
Q3 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million, versus $83.9 million total revenue in Q3 2024
Net income of $390.9 million, including a non-recurring income tax benefit of approximately $365.0 million; operating income was $29.4 million
Full-year 2025 BRIUMVI U.S. net product revenue target raised to approximately $585 million from $570-$575 million; global revenue target raised to approximately $600 million from $585 million
Completed the prior $100 million share repurchase, buying about 3.5 million shares at an average $28.55; new $100 million program authorized
IDEXX reported third quarter 2025 revenue of $1,105 million, up 13% as reported and 12% organic, and diluted EPS of $3.40, up 21%. The company raised its full-year 2025 revenue guidance to $4,270 million-$4,300 million and its EPS outlook to $12.81-$13.01, both signaling stronger expected results for shareholders.
Q3 2025 revenue of $1,105 million, up 13% as reported and 12% organic; CAG revenue up 14% and LPD up 17%.
Q3 diluted EPS of $3.40, up 21% as reported and 15% comparable; operating margin 32.1%, up 100 basis points.
2025 revenue guidance raised to $4,270 million-$4,300 million from $4,205 million-$4,280 million; EPS outlook raised to $12.81-$13.01 from $12.40-$12.76.
Freshpet reported third-quarter 2025 net sales of $288.8 million, up 14.0% from a year earlier, and net income of $101.7 million, which includes a $77.9 million tax benefit from releasing a valuation allowance. The company narrowed its full-year 2025 net sales growth outlook to about 13% and cut its Adjusted EBITDA range to $190 million to $195 million from $190 million to $210 million, while lowering its capital expenditure plan to about $140 million from about $175 million. Shareholders get higher sales but a lower top end for profit guidance, and the reported net income gain depends on a one-time tax item.
Q3 net sales rose 14.0% to $288.8 million; Q3 Adjusted EBITDA was $54.6 million versus $43.5 million a year earlier
Q3 net income of $101.7 million includes a discrete $77.9 million tax benefit; Q3 gross margin was 39.5% versus 40.4%
2025 Adjusted EBITDA guidance is $190 million to $195 million, versus $190 million to $210 million previously
2025 capital expenditure guidance is about $140 million, down from about $175 million; the company expects to be free cash flow positive for 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.